- Home
- MFM vs SGMT Comparison
MFM vs SGMT Comparison
Compare MFM & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFM
- SGMT
- Stock Information
- Founded
- MFM 1986
- SGMT 2006
- Country
- MFM United States
- SGMT United States
- Employees
- MFM N/A
- SGMT N/A
- Industry
- MFM Finance Companies
- SGMT
- Sector
- MFM Finance
- SGMT
- Exchange
- MFM Nasdaq
- SGMT Nasdaq
- Market Cap
- MFM 213.8M
- SGMT 230.3M
- IPO Year
- MFM N/A
- SGMT 2023
- Fundamental
- Price
- MFM $5.37
- SGMT $6.15
- Analyst Decision
- MFM
- SGMT Strong Buy
- Analyst Count
- MFM 0
- SGMT 7
- Target Price
- MFM N/A
- SGMT $26.57
- AVG Volume (30 Days)
- MFM 108.1K
- SGMT 461.6K
- Earning Date
- MFM 01-01-0001
- SGMT 11-12-2025
- Dividend Yield
- MFM 4.08%
- SGMT N/A
- EPS Growth
- MFM N/A
- SGMT N/A
- EPS
- MFM 0.03
- SGMT N/A
- Revenue
- MFM N/A
- SGMT N/A
- Revenue This Year
- MFM N/A
- SGMT N/A
- Revenue Next Year
- MFM N/A
- SGMT N/A
- P/E Ratio
- MFM $176.67
- SGMT N/A
- Revenue Growth
- MFM N/A
- SGMT N/A
- 52 Week Low
- MFM $4.37
- SGMT $1.73
- 52 Week High
- MFM $5.48
- SGMT $11.41
- Technical
- Relative Strength Index (RSI)
- MFM 67.73
- SGMT 30.58
- Support Level
- MFM $5.27
- SGMT $6.77
- Resistance Level
- MFM $5.38
- SGMT $7.35
- Average True Range (ATR)
- MFM 0.05
- SGMT 0.41
- MACD
- MFM 0.02
- SGMT -0.07
- Stochastic Oscillator
- MFM 96.00
- SGMT 5.57
About MFM MFS Municipal Income Trust
MFS Municipal Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in municipal bonds.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.